Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
"Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items."
"We're building on three successful phase IIs... they've had one phase II programme that failed, and they have no other ones. What they're choosing to do is really…
"Two new reports by Evaluate Ltd’s news and analysis arm, EP Vantage, highlight the wider trend."
"EP Vantage - Newsletter provider, biotech, healthcare"
"I think [Roche's (OTCQX:RHHBY) emicizumab has been shown to be that," Guy Young of the Children's Hospital Los Angeles tells EP Vantage."
"When the recently listed UK biotech's chief executive spoke to EP Vantage two years ago the focus was cancer and Imbruvica-resistant patients"
"According to E.P. Vantage’s Jacob Plieth, the El Segundo facility would also service Europe."
As ICER noted in its May whitepaper, worldwide revenues from orphan drugs topped $100 billion in 2015, and could double over the next five years, according to…